Silvia Pérez-Pérez

Dr. Silvia Pérez-Pérez

Instituto de Investigación Sanitaria Hospital Clínico San Carlos
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SPSilvia Pérez-Pérez
Silvia Pérez-Pérez
MDMaría Inmaculada Domínguez‐Mozo
María Inmaculada Domínguez‐Mozo
MGMaría Ángel García‐Martínez
María Ángel García‐Martínez
YAYolanda Aladro
Yolanda Aladro
MMMarisa Martínez‐Ginés
Marisa Martínez‐Ginés
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente

5 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SPSilvia Pérez-Pérez
Silvia Pérez-Pérez
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
GAGarcia Martinez Angel
Garcia Martinez Angel
RBRubén Ballester-González
Rubén Ballester-González
IGIsrael Nieto Gañán
Israel Nieto Gañán
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
PHERV-W ENV and syncytin-1, the envelope proteins of the human endogenous retrovirus W family (HERV-W), have been proposed as etiological factors for MS development. In addition, herpesviruses, such as the Epstein-Barr virus (EBV) and the human herpesvirus 6A/B (HHV-6A/B), have been also strongly associated with the disease. This work aims to study the possible link between viral loads and antibody titers against EBV and HHV-6A/B and the pHERV-W ENV/syncytin-1 protein/gene expression. For this purpose, we conducted a 12-month longitudinal study involving 98 RRMS patients. Peripheral blood samples were obtained from each patient. Serum antibody titers against EBV and HHV-6A/B were determined by ELISA, while viral loads were analyzed using qPCR. HLA MS-related alleles were also genotyped. pHERV-W ENV/syncytin-1 protein and gene expression levels in immune cells were assessed by flow cytometry and qPCR, respectively. We found that the 12-month variation of the pHERV-W ENV gene expression levels positively correlated with the variation of the EBV viral load, especially in those patients with high baseline EBV loads. Therefore, these results could support previous studies pointing to the transactivation of pHERV-W ENV by EBV. However, further studies are needed to better understand this possible relationship.

10 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
SPSilvia Pérez-Pérez
Silvia Pérez-Pérez
NVNOELIA VILLARRUBIA
NOELIA VILLARRUBIA
LFLucienne Costa França
Lucienne Costa França
JFJosé Ignacio Fernández-Velasco
José Ignacio Fernández-Velasco
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
Although the etiology of multiple sclerosis (MS) is still unknown, it is commonly accepted that environmental factors could contribute to the disease. The objective of this study was to analyze the humoral response to Epstein-Barr virus, human herpesvirus 6A/B and cytomegalovirus, and the levels of 25-hydroxyvitamin D (25(OH)D) and the three main short-chain fatty acids (SCFA), propionate (PA), butyrate (BA) and acetate (AA), in MS patients and healthy controls (HC) to understand how they could contribute to the pathogenesis of the disease. With this purpose, we analyzed the correlations among them and with different clinical variables and a wide panel of cell subsets. We found statistically significant differences for most of the environmental factors analyzed when we compared MS patients and HC, supporting their possible involvement in the disease. The strongest correlations with the clinical variables and the cell subsets analyzed were found for 25(OH)D and SCFAs levels. A correlation was also found between 25(OH)D and PA/AA ratio, and the interaction between these factors negatively correlated with interleukin 17 (IL-17)-producing CD4+ and CD8+ T cells in untreated MS patients. Therapies that simultaneously increase vitamin D levels and modify the proportion of SCFA could be evaluated in the future.

18 December 2019 in PeerJ
Verified
Journal Article
Open access
SPSilvia Pérez-Pérez
Silvia Pérez-Pérez
PRPablo Eguia del Rio
Pablo Eguia del Rio
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
MGMaría Ángel García-Martínez
María Ángel García-Martínez
MZMaría Francisca Zapata-Ramos
María Francisca Zapata-Ramos
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
Background: Low levels of 25-hydroxyvitamin D (25(OH)D) have been described as one of the possible environmental factors involved in multiple sclerosis (MS) etiopathogenesis. Objectives: To study epidemiology of MS and 25(OH)D serum levels of patients in Lanzarote (29°02′06″N), a region with high ultraviolet radiation values during the whole year which is located far apart from Iberian Peninsula (36°–43°N), but without genetic/ethnic differences with it. Methods: Incidence in Lanzarote was assessed according to McDonald 2005 criteria between January 2008 and December 2015 and prevalence date was 12/31/15. For 25(OH)D serum levels analyses, samples from 60 MS patients and 60 healthy donors (HD) were collected monthly in a one-year prospective study. Results: The prevalence of MS in Lanzarote was 50.0/100,000 and the incidence per year was 2.5/100,000. Median 25(OH)D levels values were 29.1 ng/ml for MS patients (maximum = 36.1 ng/ml, minimum = 22.5 ng/ml) and 27.1 ng/ml for HD (maximum = 34.8 ng/ml, minimum = 22.8 ng/ml). There were no significant differences between 25(OH)D serum levels between MS patients and HD. Conclusions: Lanzarote possesses lower prevalence and incidence values than peninsular Spain. Moreover, 25(OH)D serum levels do not differ between MS patients and HD.

18 October 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JCJuan Pablo Cuello
Juan Pablo Cuello
MGMaría Luisa Martínez Ginés
María Luisa Martínez Ginés
JDJosé Manuel García Domínguez
José Manuel García Domínguez
ATAmalia Tejeda‐Velarde
Amalia Tejeda‐Velarde
ARAlberto Lozano Ros
Alberto Lozano Ros
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente

28 January 2017 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
MRMacarena Rus
Macarena Rus
JSJose L. Santiago
Jose L. Santiago
GIGuillermo Izquierdo
Guillermo Izquierdo
ICIgnacio Casanova
Ignacio Casanova
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente